Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Mainz Biomed Expands into Switzerland with labor team w
-
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
-
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
-
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
-
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
-
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
-
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
-
Mainz Biomed Announces Stock Split
-
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement
-
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update